Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer
Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher? [Yahoo! Finance]
Summit boosts Instil, BioNTech as lead drug beats Merck's Keytruda [Seeking Alpha]
Futures Gain As Expectations For A 50bps Rate Cut Spike [zero hedge]
Private equity firms are Instil Bio, Inc.'s (NASDAQ:TIL) biggest owners and were rewarded after market cap rose by US$52m last week [Yahoo! Finance]